- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00401011
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the phase I portion is to determine the maximum tolerated dose of perifosine in combination with bortezomib in patients previously treated with bortezomib.
All patients will receive daily perifosine qhs with food. In the initial phase I study, 3 patients will be entered into a specified combination of perifosine and bortezomib cohorts. If no dose-limiting toxicity is observed, then three additional patients will be entered in cohort 4 - a full dose of bortezomib (1.3 mg/m2 on days 1, 4, 8 and 11 every 3 weeks). If this dose is tolerated it will be used for the phase II study, otherwise an intermediate dose of 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks will be employed.
The phase II study will use the maximum tolerated dose of bortezomib and perifosine. The primary objective of phase II portion is to determine the response rate (the combined CR + PR + MR) following treatment with perifosine + bortezomib in patients with multiple myeloma who have relapsed following initial front-line therapy, are refractory to their most recent therapy, and were previously treated with bortezomib. The secondary objectives of the phase II portion are;
- To further assess the safety and tolerability of perifosine in combination with bortezomib-with or without dexamethasone-in patients with multiple myeloma.
- To obtain correlative data in patients with multiple myeloma treated with perifosine in combination with bortezomib-with or without dexamethasone (NOTE Centers may choose not to participate in correlative studies).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject was previously diagnosed with multiple myeloma based on standard diagnostic criteria, as follows.
Major criteria:
- Plasmacytomas on tissue biopsy.
- Bone marrow plasmacytosis (> 30% plasma cells).
- Monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin G (IgG) >3.5 g/dL or immunoglobulin A (IgA) > 2.0 g/dL; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
Minor criteria:
- Bone marrow plasmacytosis (10 to 30% plasma cells).
- Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria.
- Lytic bone lesions.
- Normal IgM < 50 mg/dL, IgA < 100 mg/dL or IgG < 600 mg/dL.
- Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
- Any two of the major criteria.
- Major criterion 1 plus minor criterion b, c, or d.
- Major criterion 3 plus minor criterion a or c.
- Minor criteria a, b, and c or a, b, and d.
- Patients must have relapsed or refractory disease (refractory is defined as progression during treatment or within 60 days after the completion of treatment).
- Patients must have been previously treated with bortezomib. Patients may have received prior perifosine.
- Age >= 18 years at the time of signing informed consent document.
- All necessary baseline studies for determining eligibility must be obtained within 14 days prior to enrollment. (Pregnancy test must be within 7 days for women of childbearing potential.)
- Subject has an ECOG (Zubrod) performance status of 0 to 2.
- Subject must be able to adhere to the study visit schedule and other protocol requirements.
- Subject must understand and voluntarily sign an informed consent document.
- Women of child-bearing potential (WCBP)- must have a negative serum or urine pregnancy test within 72 hours prior to enrollment. In addition, all sexually active WCBP and male patients must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.
Exclusion Criteria:
- Renal insufficiency (serum creatinine levels > 3 mg/dL).
- Patients who present with either ALT or AST >= 2.5 X upper limit of normal (ULN) and/or patients with bilirubin >= 1.5 X ULN.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
- Concomitant medications that include corticosteroids (except as indicated for other medical conditions or up to 100 mgs of hydrocortisone or equivalent as premedication for administration of certain medications or blood products), chemotherapy, or other therapy that is or may be active against myeloma within 2 weeks prior to Cycle 1 Day 1. Nitrosoureas must be discontinued 6 weeks prior to Cycle 1 Day 1.
- Subjects with hemoglobin < 8.0 g/dL.
- Subjects with an absolute neutrophil count (ANC) <= 500 cells/mm3.
- Peripheral neuropathy of grade 3 or greater. Patients with painful grade 2 neuropathy are also excluded.
- Subjects with evidence of mucosal or internal bleeding and/or platelet refractory (i.e., unable to maintain a platelet count >= 50,000 cells/mm3).
- Previous history of intolerance of bortezomib or perifosine.
- Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study.
- WCBP who are pregnant or breast-feeding or men and women who are not using adequate contraception.
- Plasma cell leukemia at time of study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase II: Perifosine + Bortezomib
All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Patients will be evaluated at q 3 weeks.
If the patient has a CR, PR, MR or stable disease, they will continue treatment.
|
Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime. Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Other Names:
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Names:
|
Experimental: Phase II: Perifosine + Bortezomib + Dexa
If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
|
Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime. Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Other Names:
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Names:
Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Other Names:
|
Experimental: Phase I: Dose 1: Perifosine + Bortezomib
Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
|
Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime. Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Other Names:
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Names:
|
Experimental: Phase I: Dose 2: Perifosine + Bortezomib
Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
|
Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime. Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Other Names:
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Names:
|
Experimental: Phase I: Dose 3: Perifosine + Bortezomib
Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
|
Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime. Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Other Names:
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Names:
|
Experimental: Phase I: Dose 4: Perifosine + Bortezomib
Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
|
Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime. Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Other Names:
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Maximum Tolerated Dose (MTD). Phase II: To determine response rate.
Time Frame: Every 3 weeks
|
Phase I: To determine the MTD of perifosine in combination with bortezomib in patients previously treated with bortezomib. Phase II: The primary endpoint of the study was 6-month progression-free survival. |
Every 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase II: Tolerability and Safety
Time Frame: Every 3 weeks
|
To assess the safety and tolerability of perifosine in combination with bortezomib - with or without dexamethasone.
|
Every 3 weeks
|
Phase II: Correlative data
Time Frame: Every 3 weeks
|
To obtain correlative data in patients with multiple myeloma treated with perifosine in combination with bortezomib-with or without dexamethasone
|
Every 3 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Bortezomib
Other Study ID Numbers
- Perifosine 218
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Perifosine
-
AEterna ZentarisCompletedNon Small Cell Lung CancerUnited States
-
NCIC Clinical Trials GroupNational Cancer Institute (NCI)CompletedSarcoma | Endometrial CancerCanada
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University Health Network, TorontoNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)TerminatedHead and Neck CancerUnited States
-
NCIC Clinical Trials GroupNational Cancer Institute (NCI)CompletedMelanoma (Skin)Canada
-
Memorial Sloan Kettering Cancer CenterUniversity of Wisconsin, Madison; Duke University; AEterna ZentarisCompleted
-
National Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
Dana-Farber Cancer InstituteCompletedWaldenstrom's MacroglobulinemiaUnited States
-
Daphne FriedmanKeryx Biopharmaceuticals; Keryx / AOI Pharmaceuticals, Inc.CompletedChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States